Search research articles

ACERCA DE JoVE

Visión General Liderazgo Blog Centro de Ayuda JoVE

AUTORES

Proceso de Publicación Consejo Editorial Alcance y Políticas Revisión por Pares Preguntas Frecuentes Enviar

BIBLIOTECARIOS

Testimonios Suscripciones Acceso Recursos Consejo Asesor de Bibliotecas Preguntas Frecuentes

INVESTIGACIÓN

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archivo

EDUCACIÓN

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Centro de Recursos para Profesores Sitio de Profesores

Términos y Condiciones de Uso

Política de Privacidad

Videos de Conceptos Relacionados

Coronary Artery Disease I: Introduction

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...

Coronary Artery Disease IV: Preventive Measures

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...

Coronary Artery Disease V: Interprofessional Care

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...

Coronary Artery Disease III: Clinical Manifestations

Coronary Artery Disease III: Clinical Manifestations

Coronary Artery Disease (CAD) is a primary health risk worldwide, leading to significant morbidity and mortality. The condition arises from the buildup of atherosclerotic plaques within the coronary arteries, resulting in diminished blood supply to the heart muscle.The clinical manifestations of CAD vary widely, from asymptomatic stages to severe, life-threatening conditions. Understanding these manifestations is crucial for early diagnosis and effective management.Angina Pectoris: The Warning...

Peripheral Artery Disease I: Introduction

Peripheral Artery Disease I: Introduction

Peripheral artery disease (PAD) predominantly results from atherosclerosis, which involves the accumulation of fatty deposits, or plaques, within the walls of arteries. This causes them to narrow and harden, significantly reducing blood flow. PAD predominantly affects the legs, particularly the arteries supplying the thighs and calves. In rare cases, it may involve other arteries, including those in the arms.Etiology of PAD:The principal cause of PAD is atherosclerosis, which results from fatty...

También podría leer

Artículos Relacionados

Artículos vinculados a este trabajo por autores compartidos, revista y gráfico de citas.

Ordenar por

Same author

Effects of evolocumab on plasma coenzyme Q10 in patients with heterozygous familial hypercholesterolemia.

Atherosclerosis plus·2026

Same authorSame journal

Efficacy and Safety of Evinacumab in Japanese Patients with Homozygous Familial Hypercholesterolemia: Long-term Results from an Open-label, Single-arm, Phase 3 Trial.

Journal of atherosclerosis and thrombosis·2026

Same author

Distribution of Lipoprotein(a) Levels Among Children with Elevated Low-Density Lipoprotein Cholesterol Identified Through Universal Pediatric Lipid Screening.

Journal of atherosclerosis and thrombosis·2026

Same author

Sex Differences in the Diagnosis and Treatment of Japanese Patients With Familial Hypercholesterolemia: A Retrospective Cohort Study.

Journal of lipid and atherosclerosis·2026

Same author

Current and Future Perspectives of LDL-C Lowering Therapies 2026.

Journal of atherosclerosis and thrombosis·2026

Same author

Severe HDL-C Deficiency Caused by Acquired LCAT Deficiency: A Case Report with Lipidomic Profiling and Anti-LCAT Autoantibody Detection.

Internal medicine (Tokyo, Japan)·2026

Search research articles

Video Experimental Relacionado

Updated: Sep 9, 2025

Identifying Coronary Artery Calcification on Non-gated Computed Tomography Scans

Identifying Coronary Artery Calcification on Non-gated Computed Tomography Scans

Published on: August 28, 2018

Gota, ácido úrico y enfermedad arterial coronaria

Takuya Nakahashi¹, Hayato Tada², Kenji Sakata²

¹Division of Cardiology, Department of Internal Medicine, Takaoka City Hospital.

Journal of atherosclerosis and thrombosis

|August 31, 2025

Resumen

Este resumen es generado por máquina.

Un nivel alto de ácido úrico sérico (hiperuricemia) está relacionado con enfermedades cardiovasculares y mortalidad. Identificar a los pacientes que se benefician de la reducción del ácido úrico es crucial para controlar el riesgo cardiovascular residual.

Palabras clave:

Enfermedad arterial coronaria Tomografía computarizada de doble energía La gota Hiperuricemia Cristales de urato de monosodio Intervención coronaria percutánea Ácido úrico

Más Videos Relacionados

Calcification of Vascular Smooth Muscle Cells and Imaging of Aortic Calcification and Inflammation

Calcification of Vascular Smooth Muscle Cells and Imaging of Aortic Calcification and Inflammation

Published on: May 31, 2016

A Semi-Automated and Reproducible Biological-Based Method to Quantify Calcium Deposition In Vitro

A Semi-Automated and Reproducible Biological-Based Method to Quantify Calcium Deposition In Vitro

Published on: June 2, 2022

Videos de Experimentos Relacionados

Last Updated: Sep 9, 2025

Identifying Coronary Artery Calcification on Non-gated Computed Tomography Scans

Identifying Coronary Artery Calcification on Non-gated Computed Tomography Scans

Published on: August 28, 2018

Calcification of Vascular Smooth Muscle Cells and Imaging of Aortic Calcification and Inflammation

Calcification of Vascular Smooth Muscle Cells and Imaging of Aortic Calcification and Inflammation

Published on: May 31, 2016

A Semi-Automated and Reproducible Biological-Based Method to Quantify Calcium Deposition In Vitro

A Semi-Automated and Reproducible Biological-Based Method to Quantify Calcium Deposition In Vitro

Published on: June 2, 2022

Área de la Ciencia:

Cardiología
La bioquímica
Reumatología

Sus antecedentes:

La hiperuricemia, definida como ácido úrico sérico (UA) > 7,0 mg/dL, es un precursor de la gota.
Está asociada con hipertensión, diabetes, dislipidemia y aumento de la mortalidad.
La UA elevada se correlaciona con marcadores de aterosclerosis y disfunción endotelial, lo que sugiere un vínculo patógeno con eventos cardiovasculares.

Objetivo del estudio:

Revisar el conocimiento actual de la hiperuricemia en la enfermedad arterial coronaria (EAC).
Discutir las perspectivas futuras para el manejo de la hiperuricemia como factor de riesgo residual en pacientes con EAC.

Principales métodos:

Revisión de la literatura sobre la evidencia actual sobre la hiperuricemia y las enfermedades cardiovasculares.
Análisis de los vínculos patógenos entre la UA elevada y los eventos cardiovasculares adversos.
Examen de la gota, deposición de cristales de urato monosódico (MSU) y las implicaciones cardiovasculares.

Principales resultados:

La hiperuricemia está relacionada con el aumento de las enfermedades cardiovasculares (ECV) y la mortalidad.
La deposición de cristales de MSU puede ocurrir en las arterias coronarias, no solo en las articulaciones.
Las terapias actuales para reducir los niveles de urato no han demostrado su eficacia en la reducción de los eventos cardiovasculares relacionados con la hiperuricemia.

Conclusiones:

La hiperuricemia representa un riesgo residual significativo en pacientes con EAC.
Es fundamental identificar los subgrupos específicos de pacientes que se benefician de la reducción de la UA.
Se necesitan más investigaciones para establecer estrategias efectivas de manejo de la hiperuricemia en la EAC.